<DOC>
	<DOC>NCT01278030</DOC>
	<brief_summary>The purpose of this study is to demonstrate that cardiac resynchronization therapy (CRT) responder rate can be improved by 3-dimensional (3D) echo-guided left ventricular (LV) lead placement compared to traditional LV lead placement.</brief_summary>
	<brief_title>Real Time 3-Dimensional Echocardiography for Left Ventricular Lead Site Selection to Reduce Cardiac Resynchronization Therapy Non-Responder Rates</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patients will be implanted with an FDA approved St. Jude Medical CRTD device (i.e. PROMOTEÂ® or newer devices with similar functionality) Patients will have an approved indication per American College of Cardiology/American Heart Association/Heart Rhythm Society guidelines for implantation of a CRTD Patients will receive a new implant or an upgrade from an existing pacemaker or Implantable Cardiovertor Defibrillator with no prior Left Ventricular lead placement Patients must be in sinus rhythm at the time of enrollment visit and baseline measurements Persistent or permanent atrial fibrillation Heart transplantation Recent myocardial infarction (&lt; 90 days) Contraindication to contrast agent Are less than 18 years of age Are pregnant Are currently participating in a clinical investigation that includes an active treatment arm Have a life expectancy of less than 6 months</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>